Andrea van Elsas named CSO at Aduro Biotech

Company: Aduro Biotech Inc

Appointee: Andrea van Elsas



Andrea van Elsas, currently chief scientific officer of Aduro Biotech Europe, is to take on the position of CSO of the parent company Aduro Biotech Inc, effective 1 September. He will replace Thomas Dubensky who is stepping down to run his own company.

Dr van Elsas is a co-inventor on the original patents leading to the development of Yervoy (ipilimumab), the first checkpoint inhibitor to be approved by the US Food and Drug Administration. Yervoy was authorized in 2011 to treat melanoma. He is a co-founder of BioNovion, a Dutch start-up acquired by Aduro in 2015. Dr van Elsas held senior positions at Organon in the Netherlands which was acquired by Schering Plough Corp in 2007. Schering Plough was acquired by Merck & Co Inc in 2009. During his time at Organon and the successor companies, Dr van Elsas ran an immune oncology portfolio that included pembrolizumab.

Aduro Biotech announced the appointment on 27 July 2017.

Copyright 2017 Evernow Publishing Ltd